|
Lafora Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A significantly higher α-synuclein burden was observed in the substantia nigra (P = 0.006), ventral tegmental area (P = 0.011) and nucleus accumbens (P = 0.031) in LBD patients with depression.
|
30582885 |
2019 |
|
Lafora Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Soluble oligomeric α-synuclein accumulation in cytoplasm is believed to modify neuronal activities and intraneural Ca<sup>2+</sup> dynamics, which augment the metabolic burden in central neurons vulnerable to LBD, although this hypothesis remains to be fully tested.
|
31685859 |
2019 |
|
Lafora Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protein α-synuclein (αsyn) forms pathologic aggregates in a number of neurodegenerative diseases including Lewy body dementia (LBD) and Parkinson's disease (PD).
|
31477175 |
2019 |
|
Lafora Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated histological alterations in lysosomes and autophagosomes in the substantia nigra (SN) and cingulate gyrus (CG) in 34 patients with LBD employing antibodies against phosphorylated α-synuclein and lysosomal (lysosomal associated membrane proteins 1 and 2 (LAMP-1 and LAMP-2), cathepsin D (CTSD)) and autophagosomal (microtubule-associated protein light chain 3α (LC3A)) proteins.
|
29748975 |
2018 |
|
Lafora Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Beta-synuclein counteracts aggregation of alpha-synuclein in vitro and in animal models, however it is not clear whether this effect occurs in human Lewy body dementia (LBD) diseases.
|
29278715 |
2018 |
|
Lafora Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lewy body disease (LBD) is characterized by accumulation of aggregated α-synuclein in the central nervous system as eosinophilic cytoplasmic inclusions called Lewy bodies.
|
29909202 |
2018 |
|
Lafora Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While all four dementia types appear to involve genes associated with tau-pathology and neuroinflammation only LBD, AD and VaD appear to involve amyloid genes while LBD and FTLD share alpha synuclein genes.
|
25567624 |
2015 |
|
Lafora Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we review a rapidly growing body of literature on possible mechanisms by which extracellular α-synuclein contributes to LBD pathology, and discuss therapeutic approaches to target this form of α-synuclein to halt disease progression.
|
24468877 |
2014 |
|
Lafora Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the human hippocampus, levels of endogenous α-synuclein were increased in LBD, and the numbers of SOX2-positive cells were decreased.
|
23175842 |
2012 |
|
Lafora Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The overall methylation levels in the promoter and intron 1 of α-synuclein are rather low in controls and-in contrast to previously reported findings-are not significantly different from LBD.
|
22042430 |
2011 |
|
Lafora Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulation of the synaptic protein alpha-synuclein (alpha-syn) is a hallmark of Parkinson's disease (PD) and Lewy body disease (LBD), a heterogeneous group of disorders with dementia and parkinsonism, where Alzheimer's disease and PD interact.
|
19864570 |
2009 |
|
Lafora Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
While progressive accumulation of amyloid beta protein (Abeta) oligomers has been identified as one of the central toxic events in AD, accumulation of alpha-synuclein (alpha-syn) resulting in the formation of oligomers and protofibrils has been linked to PD and Lewy body Disease (LBD).
|
18769546 |
2008 |
|
Lafora Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abnormal folding of alpha-synuclein (alpha-syn) is thought to lead to neurodegeneration and the characteristic symptoms of Lewy body disease (LBD).
|
15953415 |
2005 |
|
Lafora Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined a large collection of pathologically confirmed LBD cases and found no evidence for multiplication of the alpha-synuclein gene, suggesting that this mechanism is not a common cause of LBD.
|
15655258 |
2004 |